Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of endocrinology"
DOI: 10.1093/ejendo/lvac006
Abstract: OBJECTIVE Poorly controlled salt-wasting (SW) congenital adrenal hyperplasia (CAH) patients often require high 9α-fluorocortisol doses as they show high levels of 17-hydroxyprogesterone (17OHP), which is a mineralocorticoid (MC)-receptor antagonist. DESIGN We investigated the renin-angiotensin-aldosterone system… read more here.
Keywords: adrenal hyperplasia; modified release; release hydrocortisone; wasting congenital ... See more keywords